Literature DB >> 3877756

B lymphocyte regulation of human hematopoiesis.

F M Uckun, D A Vallera, S L Wee.   

Abstract

Epstein Barr virus (EBV)-transformed B lymphoblastoid cell lines (BLCL) were derived from seven different individuals. The ability of BLCL supernatants to stimulate hematopoietic colony formation in vitro was tested in a conventional stem cell assay system. Supernatants promoted the growth of single (GM, E, MK) as well as multi-lineage (GEMM) colonies in bone marrow cultures. Our results indicate that EBV-transformed B lymphocytes produce cytokines that affect in vitro stem cell proliferation and differentiation. These studies demonstrate the regulatory potential of activated B lymphocytes in human hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877756

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Intracellular regulation of the production and release of human erythroid-directed lymphokines.

Authors:  N Dainiak; S Sorba
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

2.  Regulated production of a pleiotropic cytokine-platelet-derived growth factor--by differentiating erythroid cells in vitro and in vivo.

Authors:  J C Keutzer; A J Sytkowski
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

3.  E2A expression, nuclear localization, and in vivo formation of DNA- and non-DNA-binding species during B-cell development.

Authors:  Y Jacobs; C Vierra; C Nelson
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

4.  Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia.

Authors:  F M Uckun; K J Gajl-Peczalska; J H Kersey; L L Houston; D A Vallera
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.